28 C
Vientiane
Saturday, July 12, 2025
spot_img
Home Blog Page 93

Duke-NUS celebrates 20 years of medical innovation with largest ever graduating class

  • Duke-NUS Medical School’s Class of 2025 graduates 121 medical and doctoral students, including MDs, MD-PhDs, PhDs, and masters’ degrees
  • Landmark first batch of Masters in Patient Safety and Healthcare Quality graduates, unique to Southeast Asia
  • Inaugural graduates from conditional admissions pathways with NUS and SUTD
  • 41% of MD and MD-PhD graduates made bold mid-career shifts from fields such as law, PR, accounting and mental health support

SINGAPORE, May 31, 2025 /PRNewswire/ — Celebrating 20 years of transformative medical education, Duke-NUS Medical School graduated its largest cohort yet today, the Class of 2025, in a vibrant ceremony at the Ngee Ann Kongsi Auditorium in Academia attended by guest-of-honour Mr Ong Ye Kung, Minister for Health.

Mr Ong Ye Kung, Minister for Health, poses for a picture with some graduates of the Duke-NUS Medical School Class of 2025, including MDs, MD-PhDs and PhDs // Photo Credit: Duke-NUS Medical School
Mr Ong Ye Kung, Minister for Health, poses for a picture with some graduates of the Duke-NUS Medical School Class of 2025, including MDs, MD-PhDs and PhDs // Photo Credit: Duke-NUS Medical School

Marking a strategic milestone for Duke-NUS, the graduating class included 72 Doctor of Medicine (MD) graduates—five of whom are also earning PhDs—and 27 PhD candidates from the Integrated Biology and Medicine, Quantitative Biology and Medicine and Clinical and Translational Sciences programmes.

Among the MD graduates was the first group of individuals emerging from the Duke-NUS conditional admissions pathways with the National University of Singapore (NUS) and the Singapore University of Technology and Design (SUTD). These pathways are designed to attract talent from engineering, information technology and other undergraduate programmes.

Dean Professor Thomas Coffman said: “Collaborating with seven partner universities, including Duke University and NUS, these pathways are designed to allow students to earn a first degree in diverse academic majors while providing an opportunity to seamlessly transition into medicine. It’s a powerful model for developing doctors who are outstanding clinicians but also bring valuable multi-disciplinary skills into our healthcare system.”

This cohort also includes the inaugural batch of graduates of the Master’s in Patient Safety and Healthcare Quality (MPSHQ) programme, the first of its kind in Southeast Asia. The MPSHQ is focused on building highly reliable healthcare systems that are of consistent quality and safety.

The Class of 2025 represents Duke-NUS’ commitment to broadening the skillset and experience of our students, with 41 per cent of MD and MD-PhD graduates having transitioned mid-career from professions that include law, public relations, accounting and mental health peer support. Additionally, 58 per cent of the Class of 2025’s graduates are women, underscoring the School’s dedication to fostering diversity in the learning environment.

Said Dr Faith Wong Pih Yng, previously a modelmaking student and senior peer support specialist at Singapore’s Institute of Mental Health, now MD graduate, “Among the many hospital postings, what stood out most vividly was assisting in and witnessing childbirth—the intense anticipation and joy of welcoming a new life into the world was simply unmatched. Ultimately, however, the memories I cherish most are the countless hours spent with my classmates, supporting one another and peer-teaching.”  

Duke-NUS MD graduates received their degrees, awarded jointly by Duke University and the National University of Singapore, in front of friends and family, as well as notable guests, including Duke University School of Medicine Dean Professor Mary Klotman, SingHealth Group CEO Professor Ng Wai Hoe, and keynote speaker, Dr Amy Abernethy, member of Duke University’s board of trustees and co-founder of Highlander Health.

Caring and compassion underlines the Class of 2025’s accomplishments, especially beyond academia. Partaking in a wealth of community service projects, some of their cohort, such as Dr Dana Chow Wai Shin, MD, started the Healthy to Thrive initiative, the first Duke-NUS-led public health screening event dedicated to migrant workers. 

The cohort was also recognised for their outstanding achievements, which were given out the night before. Awards such as the Singapore Medical Association-Lee Foundation Prizes and Teamsmanship Awards presented to graduates who demonstrated excellence in academics, community service, and leadership.

In the aspect of research and scholarship, the Class of 2025 did not flag, publishing an exceptional 253 papers and publications in their time at Duke-NUS, several as first authors in prominent journals such as Nature Medicine, Immunity and EMBO Molecular Medicine. MD-PhD graduate Dr Katherine Nay Yaung, first author on a paper published in Lancet Rheumatology, wrote about artificial intelligence and high-dimensional technologies to diagnose and treat autoimmune diseases, and PhD graduate Dr Aishwarya Prakash, named first author and published in American Heart AssociationJournal, who found a type of peptide to have protective qualities for the heart after sustaining damage.

“The conversations I’ve had with patients emphasise a shift towards continuity of care and empowering individuals to make their own health choices. In moments where I feel overwhelmed, I remind myself that being a small part of each patient’s journey has been a privilege,” said Dr Pang Wui Ming Jeremy, recipient of the SingHealth Prize in Family Medicine, Singapore Medical Association-Lee Foundation Teamsmanship Award for exemplary team values in medicine and Duke-NUS Achievement Prize.

As Duke-NUS enters its third decade, the School continues to redefine medical education and research, nurturing the next generation of healthcare leaders who are not just exceptional doctors but visionary innovators ready to make an impact in Singapore and beyond.

About Duke-NUS Medical School

Duke-NUS is Singapore’s flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.   

For more information, please visit www.duke-nus.edu.sg 

Expanding External Opening-Up and Deepening Exchange and Cooperation

CHENGDU, China, May 31, 2025 /PRNewswire/ — The 20th Western China International Fair was held in Chengdu from May 25 to 29 under the theme “Deepen Reform for More Momentum, Expand Openness for Greater Growth.”

Expanding External Opening-Up and Deepening Exchange and Cooperation
Expanding External Opening-Up and Deepening Exchange and Cooperation

This year marks the 25th anniversary of the Fair’s establishment, attracting over 3,000 enterprises from 62 countries and regions, with Bolivia, Cuba, and Nicaragua participating for the first time. Representatives from the guest countries of honor, Hungary and Laos, indicated that through the Fair, they have reached cooperation intentions with several Chinese enterprises and see broad collaboration potential with Western China in culture, tourism, technology, and culinary sectors. The next-generation artificial sun “China’s HL-3” and other new and pioneering technologies and products were showcased at this Fair, speaking volumes about Western China’s advanced manufacturing capabilities and scientific innovation potential. Currently, 13 of China’s 80 national-level advanced manufacturing clusters are located in Western provinces.

During this Fair, various parties from Western China signed 416 investment cooperation projects with domestic and international investors, totaling 354.3 billion yuan. Economic and trade matchmaking events such as the Multinational Enterprises “Invest in Sichuan” Symposium (Italy Session) and the 15th Western China International Sourcing Conference have provided broader platforms for exchange and cooperation between Chinese and foreign enterprises.

Hong Kong-headquartered International Mediation Body Established


HONG KONG SAR – Media OutReach Newswire – 31 May 2025 – International mediation marked a significant milestone yesterday (May 30) with the establishment of the International Organization for Mediation (IOMed). The IOMed, with its headquarters in Hong Kong, is the world’s first inter-governmental international legal organisation devoted to the use of mediation in resolving international disputes.

More than 80 countries and about 20 international organisations, including the United Nations, sent senior representatives to Hong Kong to witness the Signing Ceremony of the Convention on the Establishment of the International Organization for Mediation. Member of the Political Bureau of the Communist Party of China Central Committee and Minister of Foreign Affairs of the People’s Republic of China, Wang Yi, attended the Signing Ceremony and was the first to sign the Convention on behalf of China. Altogether, 33 countries signed the Convention on-site, making them the founding members of the IOMed.

Addressing the ceremony, Mr Wang said that as an innovative step in international rule of law, the IOMed has great significance in the history of international relations. The IOMed will be headquartered in Hong Kong, whose handover is itself a success story of peaceful settlement of international disputes. He added that the success of the “one country, two systems” principle has created brighter prospects for prosperity and stability in Hong Kong.

Member of the Political Bureau of the Communist Party of China Central Committee and Minister of Foreign Affairs of the People’s Republic of China, Wang Yi, speaks at the Signing Ceremony of the Convention on the Establishment of the International Organization for Mediation and is the first to sign the Convention on behalf of China.
Member of the Political Bureau of the Communist Party of China Central Committee and Minister of Foreign Affairs of the People’s Republic of China, Wang Yi, speaks at the Signing Ceremony of the Convention on the Establishment of the International Organization for Mediation and is the first to sign the Convention on behalf of China.

Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, thanked the Central Government for its staunch support of Hong Kong, and the international community for placing their trust and confidence in the city.

“The IOMed will provide a pathway for countries – regardless of culture, language and legal system – to resolve international disputes based on mutual respect and understanding,” Mr Lee said. “This is increasingly important amid mounting geopolitical tensions.”

Mr Lee underscored that the IOMed reflected a shared confidence in mediation as a peaceful means to maintain international peace and security, as stipulated in the Charter of the United Nations.

HKSAR’s Chief Executive John Lee speaks at the signing ceremony.
HKSAR’s Chief Executive John Lee speaks at the signing ceremony.

The Chief Executive also set out Hong Kong’s advantages as an effective “super connector” and “super value-adder” and said the city would actively promote the IOMed’s valuable work in settling international disputes through mediation.

“Despite geopolitical turbulence, Hong Kong builds bridges, not walls,” Mr Lee said. “Under our unique “one country, two systems” principle, Hong Kong is the only world city that enjoys both the China advantage and the global advantage.

“We are the only common law jurisdiction in China, and the only jurisdiction in the world with a bilingual common law system in both Chinese and English. We have a long tradition of the rule of law, and our courts exercise their judicial power independently.”

With a robust, efficient and well-respected legal system as well as world-class legal and dispute resolution services professionals, Hong Kong is also the most preferred seat for arbitration in the Asia-Pacific region.

The IOMed headquarters will be located at the site of the former Wan Chai Police Station, once renovation of the Grade 2 historic building is completed.

“I’m happy to say that it could open its doors as early as the end of this year,” said Mr Lee.

“We look forward not only to welcoming its new occupants, but also to supporting them in building new bridges for a more connected, peaceful and prosperous future through mediation.”

Representatives from over 30 countries, including China and countries from Asia, Africa, Latin America and Europe, jointly signed the Convention on the Establishment of the International Organization for Mediation in Hong Kong on May 30.
Representatives from over 30 countries, including China and countries from Asia, Africa, Latin America and Europe, jointly signed the Convention on the Establishment of the International Organization for Mediation in Hong Kong on May 30.

In the afternoon, the Global Forum on International Mediation discussed topics such as mediation of disputes among countries and mediation of international investment and commercial disputes and the contributions that the IOMed can make.
Hashtag: #hongkong #brandhongkong #asiasworldcity #mediation





The issuer is solely responsible for the content of this announcement.

5.8 Kg Heroin Seized at Wattay International Airport Adds to 134 Kg Narcotics Seized in May

Dutch suspect caught with 5.8kg of heroin in travel bags at Wattay International Airport. Vientiane capital, Laos. 29 May 2025. (Photo: Ministry of Finance)

Lao authorities seized 5.8 kilograms of heroin on 29 May, concealed within aluminum-lined blankets inside two travel bags during a routine inspection that led to the arrest of a 70-year-old Dutch national. 

The operation involved officers from the Investigation and Anti-Smuggling Division working with customs officers, immigration police, and international terminal protocol staff.

This latest seizure adds to a series of major drug activities at Wattay International Airport throughout late May, with authorities confiscating over 134 kilograms of narcotics and arresting multiple international suspects in operations that highlight the country’s intensified efforts against drug trafficking.

Two days earlier on 27 May, three Malaysian nationals were arrested attempting to smuggle 103 packages of marijuana totaling 86 kilograms to Germany. The drugs were discovered during routine screening procedures, concealed within six suitcases belonging to the suspects.

On 22 May, authorities arrested a Bulgarian citizen after discovering 14 kilograms of heroin hidden in 14 packets within animal feed and coffee bags that had been prepared for international transport. 

The previous day, officers seized 31 packets of heroin totaling 28.5 kilograms from three suspicious bags belonging to a passenger from an undisclosed African nation, with the drugs similarly concealed in animal feed and coffee bags.

All four cases remain under further investigation by the Lao Ministry of Public Security.

Open Cooperation and Development Conference of “Nanjing Tour of German Enterprises” Convenes

NANJING, China, May 31, 2025 /PRNewswire/ — A news report from JSBC:

On May 23, the Open Cooperation and Development Conference of “Nanjing Tour of German Enterprises” brought together C-suite executives from Germany’s Fortune Global 500 corporations, niche market leaders (“hidden champions”), and industry leaders to explore collaborative opportunities.

Zhang Wenwu, Vice Chairman and executive director of CITIC Group, and Dr. Clas Neumann, Chairperson of the Board of German Chamber of Commerce in China – East China addressed the conference. 

At the conference, Nanjing’s high-quality business environment was presented under the theme “Transcending Boundaries through Shared Vision: Collaborative Pathways to Mutual Prosperity.”

Zhang Wenwu emphasized that the event exemplifies concrete support for German enterprises investing in China and Nanjing, reflecting CITIC’s commitment to sustainable multi-stakeholder partnerships. He vowed to strengthen CITIC’s role as a bridge, deepening Sino-German economic ties, enhancing Nanjing’s development capacity, integrating industries with technology, and upgrading financial services.

Dr. Clas Neumann noted that the event provides a vital platform for German-Nanjing collaboration. He praised Nanjing’s robust industrial base, efficient transportation, abundant educational resources, and favorable business climate as ideal for investment. According to him, Nanjing has allocated substantial resources to new technologies and sustainable development technologies. Many German companies in the city are actively engaged in sustainability-focused sectors such as wind power, hydropower, and related industries, while numerous enterprises are also investing in digital transformation to drive sustainable practices. Meanwhile, traditional industries including automotive, chemical, and pharmaceutical sectors remain crucial in propelling economic growth. Expressing strong confidence in Nanjing’s future, Neumann pledged the Chamber’s commitment to guiding more German enterprises to explore opportunities and foster win-win partnerships.

A panel discussion on “Sino-German Future Industrial Collaboration” was held. Dr. Xiao Song, Global Executive Vice President and President & CEO Siemens Greater China, delivered a keynote speech. Panelists included Armin Necker, CTO and COO of ThyssenKrupp Rothe Erde Group; Hua Ning, General Manager of DB Schenker; Huang Yixin, Chairman of Nanjing Iron & Steel Group; and Li Chao, Vice President of Estun Automation.

The event featured the launch of the Nanjing-CITIC Global Investment and Trade Service Network and the CITIC-Nanjing Multinational Innovation Hub which are meant to assist European enterprises in investing in Nanjing while supporting local enterprises in expanding overseas through comprehensive services. A business license was awarded to Yangtze River Sci-Tech Development Co., Ltd. of Jiangbei New Area, followed by multiple project signings.

Timor-Leste to Become ASEAN’s 11th Member, Says Malaysian PM

Timor-Leste will be accepted as the 11th full member of the Association of Southeast Asian Nations (ASEAN), Malaysian Prime Minister Anwar Ibrahim announced. (Photo: tirto)

Timor-Leste will be accepted as the 11th full member of the Association of Southeast Asian Nations (ASEAN), Malaysian Prime Minister Anwar Ibrahim announced.

According to Malaysia’s national news agency, Anwar said ASEAN leaders had reached a consensus to support Timor-Leste in completing the necessary steps for full membership in the regional bloc.

The decision, he stated, is for Timor-Leste to be officially admitted by the ASEAN Summit in October, pending the completion of one or two key reforms, particularly in the economic sphere. Anwar made the announcement during a press conference at the conclusion of the 46th ASEAN Summit on 27 May.

Timor-Leste first applied for ASEAN membership in 2011 and was granted observer status in 2022, allowing participation in high-level meetings. Full membership, however, has been under deliberation at the leadership level in recent summits.

Timor-Leste’s Prime Minister, Xanana Gusmão, attended the May Summit in Malaysia.

During the summit, Malaysian PM Anwar noted that ASEAN leaders have tasked ministers and senior officials with finalizing procedural steps for Timor-Leste’s admission by the upcoming 47th ASEAN Summit in October. They have also been directed to expedite negotiations on key economic agreements.

The statement indicated that they had tasked the ASEAN Coordinating Council, with the support of all relevant ASEAN Sectoral Ministerial Bodies and the ASEAN Secretariat, to extend the necessary support to facilitate Timor-Leste’s integration into the ASEAN community.

CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world’s first circular RNA drug being administrated in patients

SHANGHAI, May 31, 2025 /PRNewswire/ — Shanghai CirCode Biomed Co. Ltd. (CirCode), an innovative biotech company pioneering circular RNA therapies, recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for ischemic heart disease on May 30, 2025.

With the first patient administrated on September of 2024 in an investigator initiated trial (IIT), HM2002 is the world’s first circular RNA drug ever being used in patients. It received IND approval from the National Medical Products Administration (NMPA) of China on January 10th, 2025. HM2002 is currently the first circular RNA therapy to receive IND clearance in both China and the United States, and is also the only circular RNA drug globally approved for clinical study on patients with ischemic heart disease.

With the global aging population, ischemic heart disease shows a steadily rising incidence, and has been the leading cause of death globally for the past decades. The current standard of care shows limited effects in promoting myocardial microcirculation reconstruction and angiogenesis, leading to suboptimal efficacy and limited benefit in 10-year survival. There is an urgent unmet medical need for next generation therapies to improve patients’ prognosis and quality of life.

With the advantages of improved stability and low immunogenicity from circular RNAs, HM2002 can safely and continuously express vascular endothelial growth factor (VGEF) in the myocardium, which promotes angiogenesis, improves myocardial perfusion, and facilitates cardiac function recovery. It has demonstrated excellent safety and efficacy in the preclinical studies. In the first-in-human IIT at Ruijin Hospital initiated last year, all subjects showed significant cardiac function improvement without any drug-related adverse events.

“To promote angiogenesis and relief ischemia through VEGF overexpression is a well-tested solution, but there is a tremendous challenge to achieve an efficient, persistent, and controllable expression of VEGF in vivo. We find an excellent match between the need and the properties of circular RNA. A single dose of HM2002 can express VEGF protein for a perfect time window in vivo: long enough for efficient angiogenesis, short enough for any safety concerns. Once the microcirculation reformed, it brings long-lasting benefits to patients without the presence of HM2002 or VEGF protein,” said Dr. Chenxiang Tang, CEO of CirCode. “The IND clearances from both NMPA and FDA for HM2002 is a strong recognition for our innovation and competitiveness in the circular RNA therapeutic industry.

Dr. Yun Yang, co-founder, chairman, and chief technology officer of CirCode, stated that, “CirCode’s robust, proprietary circular RNA platform laid the foundation for the fast IND approval of HM2002. With the help of our AI tools, we were able to leap from a concept to IND approval of HM2002 in less than 2 years. We now have built a strong pipeline portfolio in various fields such as therapeutic proteins, vaccines, and in vivo CAR-T, covering multiple therapeutic areas such as cardiovascular diseases, infectious diseases, autoimmune diseases, and oncology. These pipelines have showed a favorable risk benefit profile with great efficacy and safety data in preclinical settings, many of which will enter the clinical stage within the next year. We are so excited to keep pushing the frontier of circular RNA therapy forward and providing more innovative therapies for patients.”

About CirCode

CirCode is a clinical-stage biotechnology company specializing in circular RNA therapeutics. Leveraging strong science and deep know-how, the company has built a fully integrated and proprietary platform, protected by a comprehensive global patent network, paving the way for the development of circular RNA therapeutics. Focusing on unmet medical needs, CirCode has built a robust pipeline targeting vaccines, cardiovascular diseases, autoimmune disorders, and oncology. CirCode is backed by top-tier investors and has received strong recognitions from leading pharmaceutical companies. Circode is committed to promoting the transformation of scientific and technological achievements and realizing the benefit of science and technology for mankind.

More information please visit www.circodebio.com

Or contact info@circodebio.com for business cooperation.

Illuminating ctDNA-MRD: Gene Solutions’ K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology

DA NANG, Vietnam, May 31, 2025 /PRNewswire/ — May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA)Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP).

Under the theme “Empowering the Potential of ctDNA-MRD,” 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice.

“While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation,” said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. “Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology.”

“K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact” said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. “This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region”

A First-of-Its-Kind Gathering in Asia-Pacific

Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics.

The summit featured three key sessions shared by 16 esteemed experts

K-CONNECT ACADEMIC Session :

  • The Importance of ctDNA-MRD and CGP in Precision Oncology
  • Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring
  • Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors.

K-CONNECT CASE SHARING Session

  • ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers.

K-CONNECT NEXT  LANDMARK Session

  • Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors.
  • Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation.

Beyond an Event — Establishing a Platform for Ongoing Impact

K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include:

  • K-CONNECT Webinar Series – Ongoing expert-led case discussions
  • Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions
  • Experience ctDNA-MRD Program – Hands-on implementation support for clinicians
  • Knowledge Hub – A digital platform for APAC oncology insights

Shaping the Future of Cancer Care

K-CONNECT APAC 2025 solidified Gene Solutions’ leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific.

About Gene Solutions

Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring.

With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.

Explore more information at: https://genesolutions.com/ 

MEDIA CONTACT: pr@genesolutions.com